IPP Bureau
Biostar Pharma gets FDA clearance of the IND application for a Phase 2 study of Utidelone Injection
By IPP Bureau - July 09, 2024
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Ligand to acquire Apeiron Biologics for US$100 million
By IPP Bureau - July 09, 2024
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher
By IPP Bureau - July 09, 2024
Shares and American Depositary Shares of Olink for $26.00 per Share
Health Minister Nadda visits the AIIMS Jammu
By IPP Bureau - July 08, 2024
AIIMS Jammu is a beacon of hope not only for the people of J&K, but also for that of Leh, and other neighboring states
Increasing public awareness on World Zoonoses Day
By IPP Bureau - July 08, 2024
India boasts the largest livestock population, with 536 million livestock and 851 million poultry
Aster Health Academy announces strategic partnerships with premier Hospitals across India
By IPP Bureau - July 08, 2024
The academy has secured partnerships with 15 esteemed hospitals
Viatris closes divestitures of OTC business
By IPP Bureau - July 08, 2024
Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth
Shilpa's CDMO customer placed binding purchase order
By IPP Bureau - July 06, 2024
Nephro Care India lists at 90% premium
By IPP Bureau - July 06, 2024
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur India updates on Q1 FY25
By IPP Bureau - July 06, 2024
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Biogen completes acquisition of HI-Bio
By IPP Bureau - July 06, 2024
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss
By IPP Bureau - July 06, 2024
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Merck inks MoU with Afrigen Biologics for development of mRNA vaccine technology platform
By IPP Bureau - July 05, 2024
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
GSK and CureVac restructure collaboration into new licensing agreement
By IPP Bureau - July 05, 2024
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Cardiological Society of India releases first Indian guidelines for dyslipidemia management
By IPP Bureau - July 05, 2024
Dyslipidemia is a critical risk factor for cardiovascular diseases
